Investor's Business Daily on MSN
Amgen is 'aggressively expanding' in obesity treatment; here's what investors should watch
Amgen stock toppled Friday as investors digested its "generally in-line" first-quarter report and expansion in the obesity treatment space.
Amgen has launched a late-stage program to test the feasibility of switching patients from weekly GLP-1 injections to its own ...
A team led by metabolism researcher Prof Timo D. Müller at Helmholtz Munich has developed a new approach for treating obesity ...
BMI z-score reduction of at least 0.25 is associated with lower risks for type 2 diabetes and hypertension in children with MHO and MUO.
It remains positive about its outlook for 2026, despite a stock price plunge and increased competition. Read more at ...
A study published in The Lancet reports that weekly semaglutide injections reduced heavy drinking in adults with obesity and ...
Analyses of the higher dose of Wegovy® (semaglutide 7.2 mg) and Wegovy® pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment ...
A trial of 108 adults with obesity seeking treatment for alcohol use finds a once-weekly semaglutide injection reduced heavy ...
European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results